U.S. FDA approves Stemline Therapeutics’ rare blood disease treatment

Published 7y ago

(Reuters) – The U.S. Food and Drug Administration on Friday approved Stemline Therapeutics Inc’s Elzonris for the treatment of a rare blood disease in adults and children aged two years and above. This is the first approved treatment for the condition, blastic... More »